By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Peak endocardial acceleration (PEA) sensor is a micro accelerometer sensor mounted on the tip of a unipolar ventricular pacing lead.
During ventricular contraction, it detects endocardial vibrations.If the pacemaker detects that the heart has skipped a beat or is beating too slowly, it transmits steady-state signals.
It does not send any messages if it detects that the heart is beating regularly on its own. Most pacemakers feature a unique sensor that detects body movement or the rate of respiration.
The pacemaker monitors the amplitude of detected signals when the automatic sensitivity function is active. The sensitivity is automatically increased or decreased based on the results to maintain a suitable sensing margin, consistent with the patient’s sensed P and R waves.
Pacemakers are classified into three types: single-chamber pacemakers, dual-chamber pacemakers, and biventricular pacemakers.
The Global Pacemaker sensor market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Medtronic launches the world’s smallest pacemaker with atrioventricular synchrony.India Medtronic has introduced the Micra AV, a little and entirely self-contained pacemaker that uses a minimally invasive procedure to provide patients with atrioventricular (AV) block with cutting-edge pacing technology.
This pacemaker is the first to be able to detect atrial activity without the need of a lead or other accessory in the upper chamber of the heart.
Patients with AV block have traditionally been treated with standard dual-chamber pacemakers, which are placed in the upper chest, under the skin behind the collar bone, and linked to the heart by thin wires known as ‘leads.’ Micra AV, which is the same size and form as the original Micra Transcatheter Pacing System (TPS), is linked to the heart by tiny tines and transmits electrical impulses that pace the heart through an electrode at the end of the device.
Micra AV contains numerous additional inbuilt atrial sensing algorithms that detect cardiac activity, allowing the device to change ventricular pacing to coincide with the atrium, allowing patients with AV block to receive ‘AV synchronous’ pacing treatment.
The announcement further revealed that Micra AV had been given the go-ahead by the US Food and Drug Administration (FDA) based on findings from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) , which examined the efficiency and security of accelerometer-based atrial sensing algorithms.
AV synchronisation is made possible by the Micra’s inbuilt sensor’s capacity to track and identify atrial contractions and enable synchronised pacing between the atrium and ventricle.
